International Journal of Clinical Research
International Journal of Clinical Research. 2024; 8: (9) ; 10.12208/j.ijcr.20240354 .
总浏览量: 182
天津市胸科医院 天津
*通讯作者: 曹蕾,单位:天津市胸科医院 天津;
目的 研究糜蛋白酶结合特布他林雾化治疗支气管哮喘的效果。方法 选取2019年1月至2022年1月间收治的120例支气管哮喘患者作为此次实验的观察对象,通过摇签的方式分组,摇出长签的60例患者为结合组,采用糜蛋白酶结合特布他林雾化治疗,摇出短签的60例患者为雾化组,采用特布他林雾化治疗,比较结合组与雾化组支气管哮喘患者的症状消失时间、肺功能、血清炎性指标水平、免疫球蛋白水平。结果 结合组及雾化组症状消失时间差异显著,结合组咳嗽、胸闷、哮鸣音、喘息等症状消失时间更短,有统计学意义(P<0.05)。对比结合组与雾化组肺功能指标差异明显,结合组肺功能更强,有统计学意义(P<0.05)。治疗前,结合组与雾化组血清炎性指标水平相近(P>0.05);治疗后,结合组与雾化组TNF-α、IL-4、IL-23、ECP、Hs-CRP等水平均有改善,而结合组TNF-α、IL-4、IL-23、ECP、Hs-CRP等水平更理想,具备统计学意义(P<0.05)。治疗前,结合组与雾化组免疫球蛋白水平相近(P>0.05);治疗后,结合组与雾化组IgG、IgM、IgA、IgE等水平均有改善,而结合组IgG、IgM、IgA、IgE等水平更理想,具备统计学意义(P<0.05)。结论 糜蛋白酶结合特布他林雾化治疗支气管哮喘的效果更突出,促进患者咳嗽、胸闷、哮鸣音、喘息等症状得到早日控制,提升生活质量,值得临床广泛运用。
Objective: To study the effect of chymotrypsin combined with terbutaline nebulization in the treatment of bronchial asthma. Method: 120 patients with bronchial asthma admitted between January 2019 and January 2022 were selected as the observation subjects for this experiment. They were divided into two groups by shaking the swab. 60 patients with long swabs were selected as the combination group and treated with chymotrypsin combined with terbutaline nebulization. 60 patients with short swabs were selected as the nebulization group and treated with terbutaline nebulization. The symptom disappearance time, lung function, serum inflammatory index levels, and immunoglobulin levels of bronchial asthma patients in the combination group and nebulization group were compared. Result: There was a significant difference in the disappearance time of symptoms between the combination group and the nebulization group. The combination group had a shorter disappearance time for symptoms such as cough, chest tightness, wheezing, and wheezing, with statistical significance (P<0.05). There was a significant difference in lung function indicators between the combination group and the nebulization group, with the combination group having stronger lung function and statistical significance (P<0.05). Before treatment, the levels of serum inflammatory markers were similar between the combination group and the nebulization group (P>0.05); After treatment, the levels of TNF - α, IL-4, IL-23, ECP, Hs CRP, etc. improved in both the combination group and the nebulization group, while the levels of TNF - α, IL-4, IL-23, ECP, Hs CRP, etc. were more ideal in the combination group, with statistical significance (P<0.05). Before treatment, the immunoglobulin levels in the combination group and the nebulization group were similar (P>0.05); After treatment, the levels of IgG, IgM, IgA, IgE, etc. in both the combination group and the nebulization group improved, and the levels of IgG, IgM, IgA, IgE, etc. in the combination group were more ideal, with statistical significance (P<0.05). Conclusion : The combination of chymotrypsin and terbutaline nebulization therapy has a more prominent effect on the treatment of bronchial asthma, promoting the early control of symptoms such as cough, chest tightness, wheezing, and wheezing in patients, improving their quality of life, and is worthy of widespread clinical application.
[1] 余准,黄锴川,林凯. 特布他林与异丙托溴铵雾化治疗支气管哮喘中重度急性发作的疗效及对肺功能的影响 [J]. 中国处方药, 2022, 20 (07): 114-116.
[2] 刘晓娜. 支气管哮喘急性重症患者实施布地奈德、特布他林、异丙托溴铵雾化治疗期间联合甲强龙治疗效果分析 [J]. 医药论坛杂志, 2022, 43 (12): 47-50.
[3] 张洪琼,闫天凌,钱军. 特布他林、孟鲁司特钠联合治疗支气管哮喘的临床效果及呼吸力学指标观察 [J]. 解放军医药杂志, 2022, 34 (06): 96-99.
[4] 郝婷婷,朱航,杨慧,等. 糜蛋白酶联合肺泡灌洗治疗儿童重症肺炎的疗效 [J]. 中国妇幼健康研究, 2022, 33 (05): 59-62.
[5] 李娜,方庆娟,李燕,等. 不同剂量糜蛋白酶雾化吸入联合氨溴索对慢性阻塞性肺疾病患者SIRT-1、SDF-1、FABP4水平的影响 [J]. 国际检验医学杂志, 2022, 43 (09): 1085-1089.
[6] 王和庆. 细菌溶解产物胶囊联合布地奈德混悬液、特布他林治疗支气管哮喘急性发作患者的效果 [J]. 中国民康医学, 2022, 34 (07): 11-14.
[7] 冯婉萍,姚伟豪,温巧,等. 布地奈德、特布他林联合异丙托溴铵雾化吸入治疗小儿呼吸道感染后慢性咳嗽临床疗效分析 [J]. 中国社区医师, 2022, 38 (05): 30-32.
[8] 翁翔. 特布他林联合孟鲁司特治疗儿童支气管哮喘急性发作合并支气管肺炎的效果及对肺功能、免疫功能的影响 [J]. 中外医学研究, 2021, 19 (30): 40-43.
[9] 单红卫,李丹阳. 糜蛋白酶治疗慢性阻塞性肺疾病疗效的Meta分析 [J]. 临床合理用药杂志, 2021, 14 (29): 29-31+34.
[10] 温超辉,付飞. 热哮消汤联合布地奈德、特布他林雾化治疗支气管哮喘急性发作的临床效果 [J]. 临床医学研究与实践, 2021, 6 (14): 151-153+187.
[11] 李云娜. α-糜蛋白酶雾化吸入治疗慢性阻塞性肺疾病合并社区获得性肺炎的临床效果 [J]. 中国实用医药, 2021, 16 (09): 4-6.
[12] 郑蕾芳,程纯,朱静. 布地奈德联合特布他林及异丙托溴铵雾化吸入治疗急性发作期中度儿童哮喘临床研究 [J]. 中国药业, 2021, 30 (02): 52-55.
[13] 王梅梅. 支气管哮喘患儿辅助应用布地奈德联合特布他林雾化吸入的临床疗效 [J]. 西藏医药, 2020, 41 (05): 57-59.
[14] 陈英. 布地奈德联合特布他林雾化对支气管肺炎患儿的疗效 [J]. 河南医学研究, 2020, 29 (10): 1816-1817.
[15] 徐峰. 布地奈德混悬液联合硫酸特布他林雾化液氧气驱动雾化吸入治疗毛细支气管炎的临床疗效及安全性 [J]. 中国现代药物应用, 2020, 14 (04): 124-125.